Bringing the Path Toward an HIV-1 Vaccine into Focus

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2020 Sep 11

PMID 32913360

Citations 10

Authors

Cesar J Lopez Angel

Georgia D Tomaras

Affiliations

Soon will be listed here.

Citing Articles

GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies.

Lin L, Spreng R, Seaton K, Dennison S, Dahora L, Schuster D PLoS Comput Biol. 2024; 20(11):e1012581.

PMID: 39541411 PMC: 11594404. DOI: 10.1371/journal.pcbi.1012581.

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection.

Habib A, Liang Y, Xu X, Zhu N, Xie J Int J Mol Sci. 2024; 25(4).

PMID: 38397105 PMC: 10889372. DOI: 10.3390/ijms25042432.

Statistical and machine learning methods for immunoprofiling based on single-cell data.

Zhang J, Li J, Lin L Hum Vaccin Immunother. 2023; 19(2):2234792.

PMID: 37485833 PMC: 10373621. DOI: 10.1080/21645515.2023.2234792.

Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy.

Du Y, Wu E, Gao X, Zhang J, Martin J, Rosa B Microbiol Spectr. 2022; 10(4):e0072522.

PMID: 35727047 PMC: 9431240. DOI: 10.1128/spectrum.00725-22.

Higher mucosal antibody concentrations in women with genital tract inflammation.

Sobia P, Pillay T, Liebenberg L, Sivro A, Mansoor L, Osman F Sci Rep. 2021; 11(1):23514.

PMID: 34873252 PMC: 8648917. DOI: 10.1038/s41598-021-02954-0.

References

Lewis G, DeVico A, Gallo R . Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A. 2014; 111(44):15614-21. PMC: 4226080. DOI: 10.1073/pnas.1413550111. View

Corey L, B Gilbert P, Tomaras G, Haynes B, Pantaleo G, Fauci A . Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7(310):310rv7. PMC: 4751141. DOI: 10.1126/scitranslmed.aac7732. View

Neidich S, Fong Y, Li S, Geraghty D, Williamson B, Chad Young W . Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J Clin Invest. 2019; 129(11):4838-4849. PMC: 6819135. DOI: 10.1172/JCI126391. View

Li S, B Gilbert P, Tomaras G, Kijak G, Ferrari G, Thomas R . FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest. 2014; 124(9):3879-90. PMC: 4151214. DOI: 10.1172/JCI75539. View

Yates N, Liao H, Fong Y, deCamp A, Vandergrift N, Williams W . Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39. PMC: 4116665. DOI: 10.1126/scitranslmed.3007730. View

Hansen S, Marshall E, Malouli D, Ventura A, Hughes C, Ainslie E . A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Sci Transl Med. 2019; 11(501). PMC: 6788755. DOI: 10.1126/scitranslmed.aaw2607. View

Alter G, Barouch D . Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe. 2018; 24(1):25-33. PMC: 6114134. DOI: 10.1016/j.chom.2018.06.012. View

Medlock J, Pandey A, Parpia A, Tang A, Skrip L, Galvani A . Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci U S A. 2017; 114(15):4017-4022. PMC: 5393239. DOI: 10.1073/pnas.1620788114. View

Laher F, Moodie Z, Cohen K, Grunenberg N, Bekker L, Allen M . Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020; 17(2):e1003038. PMC: 7039414. DOI: 10.1371/journal.pmed.1003038. View

10.

Rolland M, Tovanabutra S, deCamp A, Frahm N, B Gilbert P, Sanders-Buell E . Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011; 17(3):366-71. PMC: 3053571. DOI: 10.1038/nm.2316. View

11.

Fong Y, Shen X, Ashley V, Deal A, Seaton K, Yu C . Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis. 2018; 217(8):1280-1288. PMC: 6018910. DOI: 10.1093/infdis/jiy008. View

12.

Bekker L, Moodie Z, Grunenberg N, Laher F, Tomaras G, Cohen K . Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018; 5(7):e366-e378. PMC: 6028742. DOI: 10.1016/S2352-3018(18)30071-7. View

13.

Ford N, Mayer K . World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach. Clin Infect Dis. 2015; 60 Suppl 3:S161-4. DOI: 10.1093/cid/civ068. View

14.

. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4(8):e349-e356. PMC: 5555438. DOI: 10.1016/S2352-3018(17)30066-8. View

15.

Lin L, Finak G, Ushey K, Seshadri C, Hawn T, Frahm N . COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015; 33(6):610-6. PMC: 4569006. DOI: 10.1038/nbt.3187. View

16.

Burton D . Advancing an HIV vaccine; advancing vaccinology. Nat Rev Immunol. 2018; 19(2):77-78. PMC: 6425752. DOI: 10.1038/s41577-018-0103-6. View

17.

Haynes B, Mascola J . The quest for an antibody-based HIV vaccine. Immunol Rev. 2017; 275(1):5-10. PMC: 5384259. DOI: 10.1111/imr.12517. View

18.

Li S, B Gilbert P, Carpp L, Pyo C, Janes H, Fong Y . Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. J Virol. 2019; 93(21). PMC: 6803257. DOI: 10.1128/JVI.02041-18. View

19.

Saunders K, Wiehe K, Tian M, Acharya P, Bradley T, Alam S . Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science. 2019; 366(6470). PMC: 7168753. DOI: 10.1126/science.aay7199. View

20.

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View